Search

Author/Creator Vierling, John M

4. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Issue 6 (30th July 2014)

Authors:
Hézode, Christophe; Hirschfield, Gideon M; Ghesquiere, Wayne; Sievert, William; Rodriguez-Torres, Maribel; Shafran, Stephen D; Thuluvath, Paul J; Tatum, Harvey A; Waked, Imam; Esmat, Gamal; Lawitz, Eric J; Rustgi, Vinod K; Pol, Stanislas; Weis, Nina; Pockros, Paul J; Bourlière, Marc; Serfaty, Law...
Journal:
Gut
Issue:
Volume 64:Issue 6(2015)
Page Start:
948
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Issue 9973 (21st March 2015)

Authors:
Sulkowski, Mark; Hezode, Christophe; Gerstoft, Jan; Vierling, John M; Mallolas, Josep; Pol, Stanislas; Kugelmas, Marcelo; Murillo, Abel; Weis, Nina; Nahass, Ronald; Shibolet, Oren; Serfaty, Lawrence; Bourliere, Marc; DeJesus, Edwin; Zuckerman, Eli; Dutko, Frank; Shaughnessy, Melissa; Hwang, Peggy...
Journal:
Lancet
Issue:
Volume 385:Issue 9973(2015)
Page Start:
1087
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Issue 9973 (21st March 2015)

Authors:
Sulkowski, Mark; Hezode, Christophe; Gerstoft, Jan; Vierling, John M; Mallolas, Josep; Pol, Stanislas; Kugelmas, Marcelo; Murillo, Abel; Weis, Nina; Nahass, Ronald; Shibolet, Oren; Serfaty, Lawrence; Bourliere, Marc; DeJesus, Edwin; Zuckerman, Eli; Dutko, Frank; Shaughnessy, Melissa; Hwang, Peggy...
Journal:
Lancet
Issue:
Volume 385:Issue 9973(2015)
Page Start:
1087
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Issue 9973 (21st March 2015)

Authors:
Sulkowski, Mark; Hezode, Christophe; Gerstoft, Jan; Vierling, John M; Mallolas, Josep; Pol, Stanislas; Kugelmas, Marcelo; Murillo, Abel; Weis, Nina; Nahass, Ronald; Shibolet, Oren; Serfaty, Lawrence; Bourliere, Marc; DeJesus, Edwin; Zuckerman, Eli; Dutko, Frank; Shaughnessy, Melissa; Hwang, Peggy...
Journal:
Lancet
Issue:
Volume 385:Issue 9973(2015)
Page Start:
1087
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Resistance-Associated Amino Acid Variants Associated with Boceprevir plus Pegylated Interferon-α2B and Ribavirin in Patients with Chronic Hepatitis C in the Sprint-1 Trial. Issue 3 (April 2013)

Authors:
Ogert, Robert A; Howe, John A; Vierling, John M; Kwo, Paul Y; Lawitz, Eric J; McCone, Jonathan; Schiff, Eugene R; Pound, David; Davis, Mitchell N; Gordon, Stuart C; Ravendhran, Natarajan; Rossaro, Lorenzo; Jacobson, Ira M; Ralston, Robert; Chaudhri, Eirum; Qiu, Ping; Pedicone, Lisa D; Brass, Clif...
Journal:
Antiviral therapy
Issue:
Volume 18:Issue 3(2013)
Page Start:
387
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials. (November 2017)

Authors:
Lawitz, Eric; Buti, Maria; Vierling, John M; Almasio, Piero L; Bruno, Savino; Ruane, Peter J; Hassanein, Tarek I; Muellhaupt, Beat; Pearlman, Brian; Jancoriene, Ligita; Gao, Wei; Huang, Hsueh-Cheng; Shepherd, Aimee; Tannenbaum, Brynne; Fernsler, Doreen; Li, Jerry J; Grandhi, Anjana; Liu, Hong; Su...
Journal:
Lancet gastroenterology and hepatology
Issue:
Volume 2:Number 11(2017)
Page Start:
814
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗